TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.
Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of third quarter 2026 results, which are expected to be released on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.